80 results
Page 2 of 4
8-K
EX-99.1
te7i3w
19 Oct 21
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
9:24am
424B3
841pinehfazaqpxjn
16 Aug 21
Prospectus supplement
12:00am
424B3
cmos8io4q6y5g70iyjd
12 Jul 21
Prospectus supplement
4:18pm
8-K
EX-10.1
nd9sqxf3pwp2u52
2 Jul 21
Entry into a Material Definitive Agreement
4:01pm
S-8
EX-4.5
pfuczhs7x9au8qhglk
25 Jun 21
Registration of securities for employees
4:44pm
424B3
foz9093qmr0t56yymnsr
24 Jun 21
Prospectus supplement
5:16pm
8-K
EX-10.1
sgzqq7 vnfqoebt5
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
424B3
ogka621
13 May 21
Prospectus supplement
9:11pm
424B3
kbylij6esppv2iq
11 Mar 21
Prospectus supplement
9:56pm
424B3
7pmz2n1r1zp2zojethv4
26 Jan 21
Prospectus supplement
5:02pm
8-K
EX-10.1
ai37cr00fshbar 5x4
26 Jan 21
Entry into a Material Definitive Agreement
9:16am
424B4
qrik46
8 Jan 21
Prospectus supplement with pricing info
9:38pm
8-K
EX-99.1
ufm9brzns
5 Jan 21
Sven Guenther, Ph.D., our executive vice president, research and development; and Summary Compensation Table
9:10am